International Funding for Malaria Control in Relation to Populations at Risk of Stable Plasmodium falciparum Transmission by Snow, Robert W et al.
International Funding for Malaria Control in
Relation to Populations at Risk of Stable
Plasmodium falciparum Transmission
Robert W. Snow
1,2*, Carlos A. Guerra
1,3, Juliette J. Mutheu
1, Simon I. Hay
1,3
1 Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, Kenyan Medical Research Institute (KEMRI)–University of Oxford–Wellcome Trust
Collaborative Programme, Nairobi, Kenya, 2 Centre for Tropical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom, 3 Spatial Ecology and
Epidemiology Group, Department of Zoology, University of Oxford, Oxford, United Kingdom
Funding: RWS is a Wellcome Trust
Principal Research Fellow (#079080).
CAG is supported by a Wellcome
Trust Project grant (#076951). SIH is
funded by a Senior Research
Fellowship from the Wellcome Trust
(#079091). This work forms part of
the output of the Malaria Atlas
Project (MAP, http://www.map.ox.ac.
uk), principally funded by the
Wellcome Trust, U.K. The funders
had no role in study design, data
collection and analysis, decision to
publish, or preparation of the
manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Sanjeev Krishna,
University of London, United
Kingdom
Citation: Snow RW, Guerra CA,
Mutheu JJ, Hay SI (2008)
International funding for malaria
control in relation to populations at
risk of stable Plasmodium falciparum
transmission. PLoS Med 5(7): e142.
doi:10.1371/journal.pmed.0050142
Received: February 4, 2008
Accepted: May 14, 2008
Published: July 22, 2008
Copyright:  2008 Snow et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: DFID, Department
for International Development, UK;
GFATM, The Global Fund to fight
AIDS, Tuberculosis and Malaria;
MDG, Millennium Development
Goals; p.a., per annum; PfMEC,
Plasmodium falciparum malaria
endemic country; PfPAR,
population(s) at risk of P. falciparum
malaria; PfPARstable, population(s)
at stable risk of P. falciparum malaria;
PMI, President’s Malaria Initiative;
RBM, Roll Back Malaria; USAID,
United States Agency for
International Development; WMR,
World Malaria Report.
* To whom correspondence should
be addressed. E-mail: rsnow@
nairobi.kemri-wellcome.org
ABSTRACT
Background
The international financing of malaria control has increased significantly in the last ten years
in parallel with calls to halve the malaria burden by the year 2015. The allocation of funds to
countries should reflect the size of the populations at risk of infection, disease, and death. To
examine this relationship, we compare an audit of international commitments with an
objective assessment of national need: the population at risk of stable Plasmodium falciparum
malaria transmission in 2007.
Methods and Findings
The national distributions of populations at risk of stable P. falciparum transmission were
projected to the year 2007 for each of 87 P. falciparum–endemic countries. Systematic online-
and literature-based searches were conducted to audit the international funding commitments
made for malaria control by major donors between 2002 and 2007. These figures were used to
generate annual malaria funding allocation (in US dollars) per capita population at risk of stable
P. falciparum in 2007. Almost US$1 billion are distributed each year to the 1.4 billion people
exposed to stable P. falciparum malaria risk. This is less than US$1 per person at risk per year.
Forty percent of this total comes from the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Substantial regional and national variations in disbursements exist. While the distribution of
funds is found to be broadly appropriate, specific high population density countries receive
disproportionately less support to scale up malaria control. Additionally, an inadequacy of
current financial commitments by the international community was found: under-funding
could be from 50% to 450%, depending on which global assessment of the cost required to
scale up malaria control is adopted.
Conclusions
Without further increases in funding and appropriate targeting of global malaria control
investment it is unlikely that international goals to halve disease burdens by 2015 will be
achieved. Moreover, the additional financing requirements to move from malaria control to
malaria elimination have not yet been considered by the scientific or international community.
The Editors’ Summary of this article follows the references.
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The Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFTAM) [1–3] was established in January 2002 as an
independent ﬁnancing body to attract, manage, and disburse
funds to control these three major diseases of poverty. This
innovative mechanism for results-based health care ﬁnancing
had by the end of 2007 committed US$10 billion to 136
countries [1,2]. The GFATM responds to nationally docu-
mented demand for antimalarial interventions and commod-
ities. Countries are encouraged to submit proposals every
year, which are reviewed independently by a technical review
panel before the GFATM board makes a decision [4,5]. The
GFATM state that their funding priorities are to countries/
regions with the highest disease burdens and weakest
ﬁnancial capacity to support disease control [1,6]. By the
end of 2006 GFATM support represented an estimated 64%
of all international funding for malaria control worldwide
[6,7]. Rather than displace international support for malaria,
new funding initiatives have emerged in recent years parallel
to the GFATM, notably the World Bank global strategy and
booster program [8] and the US President’s Malaria Initiative
(PMI) [9]. Bilateral agencies also continue to expand their
support to countries as part of combined efforts to meet the
Millennium Development Goals (MDG) [10,11]. As the
funding capacity for global malaria control increases, it is
important to examine the allocation of ﬁnancing in relation
to the distribution of populations most at risk of the disease;
that is, to measure the equity of disbursements.
A perennial problem facing needs-based allocation of
resources for malaria is the quantiﬁcation of requirements
based upon reliable descriptions of national populations at
risk of infection and disease burden [12]. We recently
published an evidence-based global distribution map of
malaria risk that shows the most precise and contemporary
description of the spatial limits of stable and unstable P.
falciparum risk [13]. In the present study we use descriptions of
stable malaria risk to categorize the biological vulnerability of
P. falciparum malaria–endemic countries (PfMECs) and exam-
ine the per capita ﬁnancial contributions approved by the
GFATM, domestic funding, and support from other donors.
Methods
Defining Populations atRisk ofP.falciparumMalaria in2007
The contemporary spatial distribution of P. falciparum
malaria and populations at risk of P. falciparum malaria
(PfPAR) are described in detail elsewhere [13]. In brief, data
on national case reporting, national and international
medical intelligence, climate, and aridity were used to
iteratively, and conservatively, deﬁne the margins of stable
and unstable P. falciparum transmission globally. A deﬁnition
of stable malaria of a minimum average of one clinical case
per 10,000 population per annum (p.a.) in a given admin-
istrative unit was used. The historical deﬁnitions of stable and
unstable malaria are rarely measured, as they are entomo-
logically based metrics. The revised stable–unstable classi-
ﬁcation of P. falciparum Annual Parasite Incidence was based
on a review [14] of the statistical, logistical, programmatic,
and pragmatic reasons underpinning the levels used to deﬁne
action points during the Global Malaria Eradication Pro-
gramme [14–18]. This deﬁnition allows the use of widely
available surveillance data that provide a measurable guide to
the frequency of malaria exposure at a global level [14]. No
transmission was assumed where assembled intelligence
stated no malaria risk, because (i) not a single P. falciparum
clinical case had been reported to national reporting systems
over several years, or (ii) where temperature was too low for
sporogony to complete within the average life span of the
local dominant vector species, or (iii) conditions were too
arid for anopheline mosquito survival. Unstable malaria was
used to deﬁne areas where transmission was biologically
plausible and/or had been documented but where incidence
was likely to be less than one case per 10,000 population p.a.
[14–18]. We estimated that the global population at any risk
of P. falciparum transmission in 2007 was 2.37 billion across 87
countries and included 0.98 billion people living in areas
deﬁned as low, unstable transmission risk (see Figure 1).
Country-level extractions of the population densities
residing in unstable and stable P. falciparum–endemic areas
were undertaken using the Global Rural Urban Mapping
Project (GRUMP) alpha version that provides gridded
population counts and population density estimates for the
years 1990, 1995, and 2000, both adjusted and unadjusted to
the United Nations’ national population estimates [19]. We
used the adjusted population counts for the year 2000 and
projected them to 2007 by applying national, medium variant,
intercensal growth rates by country [20] using methods
previously described [21]. This resulted in a contemporary
global population surface and a 1 3 1 km spatial resolution,
describing populations living in unstable and stable P.
falciparum–endemic areas in each of the 87 PfMECs. The
populations at risk were then calculated by overlaying the
malaria risk map on the population surface in a geographic
information system (ArcView GIS 3.2, ESRI, 1999).
We used populations at any risk of P. falciparum malaria
infection and those living in areas of stable transmission as
two strata of malaria risk in each country. Stable risk
represents a more realistic estimate of populations at risk
of signiﬁcant disease burdens but does not distinguish
between those populations exposed to infrequent malaria
infection risks and those subject to repeated high infection
and thus high disease burden risks [14,22]. In the present
analyses, emphasis is given to populations at risk of stable P.
falciparum malaria (PfPARstable), as they have the greatest
public health needs that can be addressed using combinations
of currently proven interventions and are the focus of the
Roll Back Malaria (RBM) initiative since 1998 [23,24]. The
GFATM uses eight regional groupings in its presentation of
country applications; we have adapted these categories by
collapsing the regions into four groupings: Africa, South East
Asia/Western Paciﬁc, Middle East/Eastern Europe, and the
Americas/Caribbean (the countries in each region are deﬁned
in Table S1 and the footnote to Table 1).
We have not developed a similar risk map for the spatial
extents of P. vivax. There are important differences in the
biology of P. vivax transmission [25,26], the skill with which
the parasite can be diagnosed clinically [27], and a less well
deﬁned relationship between transmission intensity and
disease outcome. These factors all make an informed
cartography and modelling of P. vivax distribution consid-
erably more complex than for P. falciparum. We do not
underestimate the likely disease burden of P. vivax malaria
[28,29] and recognize that the global extent and public health
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is with this caveat that we have used the risks of the most
clinically important and best-mapped human malaria para-
site, P. falciparum, to articulate biological needs for malaria
control investment. In addition, since P. falciparum is easier to
control [14–18], dealing with this parasite is more often
regarded as a national and international priority.
GFATM-Approved Funding for Malaria Control 2002–2007
We have focused on approved funding between round one
(2002) and round seven (2007), rather than on signed
contracts or disbursed funds. Approved funding is the
expressed needs of country or region in applications that
have been reviewed for technical content and approved by
the GFATM. Not all funding has been disbursed and not all
contracts would have been signed by the end of 2007; these
are difﬁcult to reconcile between rounds of GFATM funding
and between countries. Therefore our focus was on the funds
approved by the GFATM under the assumption that these
approved funds reﬂect need and do not capture the
idiosyncrasies of delayed funding disbursement or cessation
of funding due to poor performance or governance [30]. This
therefore represents the ability of the GFATM to respond to
need, rather than the ability of a government to deliver.
Figure 1. P. falciparum Malaria Risk Defined by Annual Parasite Incidence, Temperature, and Aridity
Populations at risk in areas definedas havingstable (darkpink) andunstable transmission(light pink) were extractedfor each of the 87 PfMECs. From [13].
doi:10.1371/journal.pmed.0050142.g001
Table 1. Regional Populations (Millions) at Any and Stable P. falciparum Risk in 2007, Annualized GFATM Approved Funding (Millions,
US Dollars) and Annualized Non-GFATM Malaria Funding (Millions, US Dollars)
Region PfPAR
Any Risk
PfPAR
Stable Risk
Annualized
GFATM Support
Annualized
Non-GFATM Support
Annualized
Combined GFATM and
Non-GFATM Support
Africa 656.3 (27.7%) 640.1 (46.1%) 312.0 (77.7%) 345.8 (58.6%) 657.8 (66.3%)
Americas/Caribbean 91.4 (3.9%) 41.1 (3.0%) 12.8 (3.2%) 74.3 (12.6%) 87.1 (8.8%)
South Asia/Western Pacific 1,479.9 (62.3%) 655.0 (47.2%) 66.5 (16.6%) 142.2 (24.1%) 208.7 (21.1%)
Middle East/East Europe 146.0 (6.2%) 52.1 (3.8%) 10.5 (2.6%) 27.4 (4.6%) 37.9 (3.8%)
Totals 2,373.6 1,388.3 401.8 589.7 991.5
Figures in parentheses are percentages by column totals. Africa: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Co ˆte
d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali,
Mauritania, Mayotte, Mozambique, Namibia, Niger, Nigeria, Republic of the Congo, Rwanda, Sa ˜o Tome ´ and Prı ´ncipe, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Swaziland,
Tanzania, Togo, Uganda, Zambia, Zimbabwe. Americas/Caribbean: Belize, Bolivia, Brazil, Colombia, Dominican Republic, Ecuador, French Guiana, Guatemala, Guyana, Haiti, Honduras,
Nicaragua, Panama, Peru, Suriname, Venezuela. South Asia/Western Pacific: Bangladesh, Bhutan, Cambodia, China, India, Indonesia, Lao People’s Democratic Republic, Malaysia, Myanmar,
Nepal, Papua New Guinea, Philippines, Solomon Islands, Sri Lanka, Thailand, Timor-Leste, Vanuatu, Viet Nam. Middle East/East Europe: Afghanistan, Iran, Kyrgyzstan, Pakistan, Saudi Arabia,
Tajikistan, Yemen.
doi:10.1371/journal.pmed.0050142.t001
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were assembled from the GFATM Web site [3]. It was difﬁcult
to attribute funding to individual countries uniquely where
support was awarded for regional initiatives. Such multi-
country proposals included those in southern Africa (South
Africa, Mozambique, and Swaziland), the Andean region in
the Americas (Colombia, Ecuador, Peru, and Venezuela), and
the Western Paciﬁc region (Solomon Islands and Vanuatu). In
these cases we assumed a proportional allocation by country
PfPAR relative to the total PfPAR for the region (e.g., PfPAR
estimated for Ecuador is 18.8% of the total PfPAR for all four
Andean countries combined [5.8 million/30.8 million people];
hence funds assumed for Ecuador were 18.8% of the total
funds of the proposal).
Clearly, the approval of awards for malaria by the GFATM
has beenvariableacross the 5-y interval.Duringround one very
few malaria awards were approved, representing only 14% of
all funds approved in 2002 [31]. In contrast, during round four,
a total of US$631 million was awarded to 22 countries. In
addition,excludingregional submissions, 21 countrieshad only
a single award approved between rounds one and seven, 35
countries were approved in at least two submissions, and ten
c o u n t r i e sw e r ea p p r o v e df u n d i n gi nt h r e eo rm o r er o u n d s .
Without trying to weigh each timed award per country we have
aggregated the combined awards across all approved rounds
(one to seven) to represent a single GFATM commitment to
each PfMEC and taken an annual average of this ﬁgure over the
6 y to reﬂect the averaged approved funding for malaria
control per country p.a. This annual estimate has no temporal
midpoint, as funds awarded in 2007 have yet to have signed
contracts orbedisbursedandincludethe5 ypost-2007,andare
simply a p.a. commitment quantiﬁed over the number of years
of existing funding rounds.
Defining Additional National and External Support for
Malaria Control by Country
The GFATM seeks not to displace existing national-level
funding for malaria control [1–3], rather to provide addi-
tional resources to meet internationally agreed targets. The
World Malaria Report (WMR) produced by WHO and
UNICEF [32] provides information on the amount of money
spent by national governments on malaria control and
prevention each year since 1998. These funds are domestic
commitments or expenditure on malaria reported by govern-
ments to the WHO and converted to US dollars using the
contemporary ofﬁcial exchange rate. These data have been
used by others to estimate unmet ﬁnancial needs for malaria
control [33], and here we have assumed that the most recent
domestic funding ﬁgure provided in the WMR is a reﬂection
of (but not the actual) national ﬁnancial commitment to
malaria control. Data for 23 countries were not available in
the WMR, and we assumed that these countries were unable
or unwilling to provide these data. The wide variation in
reported commitments per capita between countries pre-
cluded the use of a neighbouring country average. We chose
to assume that countries not reporting a domestic funding
commitment provided funds equivalent to the lowest
rounded ﬁgures in their respective regions as follows: Africa
US$30,000 p.a.; South East Asia/Western Paciﬁc US$50,000
p.a.; Middle East/Eastern Europe US$100,000 p.a., and the
Americas/Caribbean US$100,000 p.a. (Table S1).
Additional malaria-speciﬁc support is provided to coun-
tries as direct grants or, in the case of the World Bank, as very
low interest long-term loans. These additional funding
partners include bilateral and multilateral agencies: the
UK’s Department for International Development (DFID)
supporting Kenya, Nigeria, and Mozambique [34]; the United
States Agency for International Development (USAID), which
provides recipient country data on its Web site [35]; and the
PMI, launched by US President G. W. H. Bush in June 2005
with the aim of spending US$1.2 billion in 15 African
countries over 5 y [9]. During the ﬁrst phase of PMI activities
in 2005, three countries were included in the programme
(Angola, Tanzania, and Uganda); funding and activities began
in an additional four countries in 2007 (Mozambique,
Senegal, Malawi, and Rwanda), and although initial consulta-
tions have been completed in Benin, Ghana, Mali, Liberia,
Ethiopia, Madagascar, Zambia, and Kenya, there are no
details of proposed funding allocations for these countries.
The World Bank global strategy and booster program has
invested US$432 million in 15 countries since 2005, including
two new projects approved in Mozambique and Kenya for
2007–2008 [8] and a multi-country, multi-sector programme
covering the Senegal River Basin (Senegal, Mali, Mauritania,
and Guinea) which was difﬁcult to audit in terms of malaria-
speciﬁc and country-speciﬁc allocations and was therefore
excluded from the ﬁnal analysis (US$42 million for the whole
program). Additional World Bank support for periods of
between 5 and 7 y from 2002 was assumed as described by
Narasimhan and Attaran [36] for ten countries.
Many other important initiatives provide additional sup-
port through humanitarian sponsorship or tariffs for
commodities [37–39], as part of technical assistance [40],
humanitarian assistance [41], broader development assistance
from regional banks [42–44], and nongovernment support by
varied international and regional NGO partnerships in-
country [45–47]. These alternative funding sources were
explored through Web searches; however, none of these
initiatives provided adequate detail on project–country-
speciﬁc funding or commodity distribution to enable a
comprehensive analysis of committed ﬁnances. There were
two important exceptions: the Bill & Melinda Gates Founda-
tion US$35 million donation to PATH to support compre-
hensive malaria control in Zambia between 2005 and 2014
[48] and the Arabian peninsula countries’ 2007 announce-
ment that they would provide US$17 million to Yemen over 5
y to implement its malaria elimination plans [49].
We used information from the World Bank, DFID, USAID,
PMI, the domestic funding estimates in the WMR, and the
Gates Foundation and Arabian donations to compute a non-
GFATM estimate of ﬁnancial support for malaria control.
Data from bilateral, multilateral, or donation support were
assembled over multi-year periods between 2004 and 2007
but aggregated to an average in US dollars over the reporting
period per donor commitment p.a. per country.
Results
Regional P. falciparum Risks in Relation to Overall GFATM
and Non-GFTAM Funding
The vast majority of people living at any risk of P. falciparum
transmission worldwide are in South East Asia/Western
Paciﬁc (62.3%), followed by Africa (27.7%), the Middle East/
East Europe (6.1%), and the Americas/Caribbean (3.8%; Table
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population at P. falciparum risk living in areas of stable
endemic malaria are different (Table 1); values are almost
equal in Africa (46.1%) and South East Asia/Western Paciﬁc
(47.2%). Total estimated PfPAR by country ranged from
58,568 people in Suriname to 950 million in India. PfPAR-
stable ranged from approximately 8,000 (Suriname) and
19,000 (Djibouti) to between 130,000 (Sa ˜oT o m e ´a n d
Prı ´ncipe) and 140,000 (French Guiana and Guyana) and to
approximately 30–415 million people in eight countries
(Pakistan, Tanzania, Myanmar, Ethiopia, the Democratic
Republic of Congo, Indonesia, Nigeria, and India). Five
countries had no populations living under conditions of
stable transmission (Belize, Cape Verde, Mayotte, Tajikistan,
and Kyrgyzstan; Table S1).
Seventy-seven countries had been approved for funding for
malaria control by the end of 2007, including Georgia, where
malaria transmission involves only P. vivax and is excluded
from the analysis of funding presented here. Table S1
provides country-level estimates of the annual GFATM–
approved funding per capita population living in areas of
any or stable P. falciparum risk from 2002 to 2007. Seventy-six
of the 87 PfMECs had been approved funding by round seven,
either directly (n ¼ 69) or through regional applications (n ¼
7), amounting to a total of US$2.41 billion through 133
separate grant applications since round one. Eleven PfMECs
have never been awarded GFATM support for malaria (Belize,
Botswana, Brazil, Cape Verde, the Democratic Republic of
Congo, Dominican Republic, French Guiana, Mayotte, Ma-
laysia, Panama, and Saudi Arabia). Three of these countries
have zero PfPARstable (Belize, Cape Verde, and Mayotte).
Approximately 26.5 million people are at risk of stable
transmission in the remaining countries not receiving
funding. Total funds approved to countries by the GFATM
in a single round ranged between US$1.5 million and US$84.5
million (Table S1). On average, populations living in stable,
endemic areas of the world have been approved funding by
the GFATM at US$2.9 per capita-at-risk p.a. since 2002.
African populations under stable transmission have been
awarded US$1.5 annually per capita-at-risk, the Americas/
Caribbean US$10.3 per capita-at-risk p.a., Middle East/East
Europe US$1.1 per capita-at-risk p.a. and the lowest per
capita commitment noted in South East Asia/West Paciﬁc
(US$0.7 per capita-at-risk p.a.).
Of the 74 countries with populations exposed to stable
endemic transmission that have been allocated malaria funds
by the GFATM, the average annual per capita at stable risk
awarded amounts ranged from US$0.01 in Myanmar to
US$147 in Suriname. Twenty-four countries had an average
annual award of more than US$1 per capita at stable risk p.a.,
12 were located in Africa and these were predominantly
smaller countries (Sa ˜o Tome ´ and Prı ´ncipe, Burundi, Rwanda,
Djibouti, The Gambia, Gabon, Equatorial Guinea, and Swazi-
land [Figure 2; Table S1]). Only seven countries had average
annual awarded funding exceeding US$4 per capita at stable
risk (Sa ˜o Tome ´ and Prı ´ncipe, Djibouti, Equatorial Guinea,
Guyana, Venezuela, Iran, and Suriname [Figure 2; Table S1]).
The enumerated non-GFATM malaria funding to each
country amounted to US$589.8 million on an average year
between 2002 and 2007, approximately 59% of the estimated
combined GFATM and non-GFATM annualized commit-
ments. The non-GFATM funds and their sources are shown
by country in Table S1. On an average annual per capita at
stable risk basis, the least non-GFATM support per person
Figure 2. Mean Approved GFATM Funding for 87 PfMECs Expressed as US Dollars (USD) Per Capita at Stable P. falciparum Risk Per Annum
Countries indicated by hatching are those with no areas of stable risk.
doi:10.1371/journal.pmed.0050142.g002
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highest amounts in Saudi Arabia (US$19.7), Suriname
(US$20.3), and Iran (US$42.4). Twenty-one countries had an
average of more than US$1 non-GFATM per capita support
for malaria, seven countries had a non-GFATM annual per
capita-at-stable risk commitment in excess of US$4; none
were located in Africa (Bolivia, Guyana, Iran, Panama, Saudi
Arabia, Suriname, and Venezuela; Figure 3; Table S1).
When combined with GFATM per capita support to
populations in stable endemic areas, ten countries had an
estimated combined per capita annual commitment of more
than US$4 per person in an average year (Equatorial Guinea,
Panama, Sa ˜o Tome ´ and Prı ´ncipe, Guyana, Bolivia, Venezuela,
Saudi Arabia, Djibouti, Iran, and Suriname [Figure 4; Table
S1]) compared to 34 countries where the combined annual
commitment was less than US$1 per capita at stable risk,
including 16 countries where annual malaria support was less
than US$0.5 (Figure 4). These 16 countries encompass
approximately 710 million people living under conditions of
stable transmission, or 50% of the global population exposed
to these risks of malaria transmission, and include seven of the
poorest countries in Africa (Co ˆte d’Ivoire, Republic of the
Congo, Chad, Mali, Democratic Republic of the Congo,
Somalia, and Guinea) and two of the most densely populated
stable endemic countries in the world (Indonesia and India).
Discussion
Global and Regional Need for Malaria Control Versus
Financial Disbursement
Plasmodium falciparum malaria continues to cause a huge
global disease burden with an estimated 0.5 billion clinical
episodes [22] and is the direct cause of over a million deaths
in Africa each year [50,51]. The international community has
renewed its commitment to its control as a speciﬁc
component of the MDGs [10,11] and are reconsidering
prospects for its elimination in areas where feasible [52,53].
The ten years since the launch of the RBM initiative [24,54]
have witnessed a substantial increase in donor assistance to
ﬁght malaria.
Between 2002 and 2007 we estimate that a minimum
annual average of approximately US$1 billion is committed
by the international ﬁnancing agencies and domestic sources
across 87 PfMECs. In these countries 2.37 billion people are at
risk of infection, including 1.4 billion people who live in areas
where the risks of infection are classiﬁed as stable and likely
to bear the highest clinical and economic burdens (Table 1).
The most important contributor to malaria ﬁnancing is the
GFATM. In the 6 y since the inception of the GFATM, over
US$2.4 billion has been approved for funding across 76
PfMECs, 41% of the estimated combined annual support to
the P. falciparum world. Of the approved funding, most (78%)
was targeted at the continent with the highest concentration
of people living under conditions of stable transmission and
representing the poorest countries globally: Africa (Table 1).
Africa also received more than half (59%) of the audited non-
GFATM ﬁnancing, including notable awards made by the
bilateral agencies of the US and the UK, the World Bank
global strategy and booster program, and PMI.
Given the scarcity of domestic resources and the greatest
disease burden across much of the African continent, this
allocation of global malaria ﬁnancing seems appropriate, if
taken at face value, but in fact it might not be adequate.
Funding commitments by the GFATM and other sources also
Figure 3. Mean Approved Non-GFATM Funding for 87 PfMECs Expressed as US Dollars (USD) Per Capita at Stable P. falciparum Risk Per Annum
Countries indicated by hatching are those with no areas of stable risk.
doi:10.1371/journal.pmed.0050142.g003
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population at risk areas of the Americas/Caribbean and Mid
East/East Europe (Table 1). However, the South East Asia/
Western Paciﬁc region of the world is home to 47% of the
global population at risk of stable P. falciparum transmission,
yet these countries were awarded only 17% of the GFATM
funding between 2002 and 2007 and 24% of the non-GFATM
support, representing a combined annualized per capita at
stable risk commitment of approximately US$1 (Table 1).
India, Indonesia, and Myanmar combined have approxi-
mately 526 million people living under conditions of stable P.
falciparum infection risk, or 38% of the global PfPARstable.
Yet India has been approved the equivalent of US$0.03 per
capita-at-risk of stable malaria p.a. by the GFATM, and its
alternative funding sources amount to only US$0.20 per
capita-at-risk p.a. (Table S1). GFATM support for Indonesia
and Myanmar was equivalent to only US$0.12 and US$0.01
per capita-at-risk p.a., respectively. These are clear examples
of the importance of examining ﬁnancial planning and
commitments against objectively mapped criteria of malaria
risk. If development goals have a global horizon, reducing the
worldwide burden of malaria by 50% by 2015 [10] would fail
by a large margin unless international support were directed
to those few countries likely to harbour the highest
populations at risk.
Identifying Financial Need for Malaria Control at the
National Level
Country-level examinations of the data revealed that 11
countries have not received any GFATM support but
represented extremely low (n ¼ 7) or zero (n ¼3) populations
exposed to stable P. falciparum risk and/or had a high domestic
support or capacity for malaria control (e.g., Saudi Arabia
and Brazil; Table S1). Conversely, the per capita under-
funding of India, Indonesia, and Myanmar has been
described, but two additional countries should be highlighted
for which a low funding commitment is evident when
computed as per capita-at-risk. Nigeria, the second-largest
PfPARstable country in the world with almost 135 million
people at risk, was awarded only US$0.12 per capita-at-risk
p.a. by the GFATM between 2002 and 2007 (20% of all
enumerated per capita investment). Pakistan, with 31 million
people at risk, was awarded only US$0.1 per capita p.a.
support by the GFATM and has very little domestic or other
external support (approximately US$0.016 per capita p.a.).
The example of Suriname shows how much funding can be
committed by the GFATM to a comparatively small popula-
tion at risk and with an existing substantial ﬁnancial non-
GFATM support. Here we found that the GFTAM had
approved US$147 per capita at stable risk p.a. and the
combined commitments to malaria amounted to US$167 per
capita p.a. Suriname represents an outlier in the analysis and
is expected to achieve rapid scale-up results toward achieving
its malaria MDG [55].
We have not analysed the performance consequences of
increased international support to malaria since 2002.
Analysis of commodity procurements through GFATM has
been used to support the successes of the mechanism in
reaching international coverage targets rather than actual
data on intervention coverage or health impact [4,56]. Claims
of performance success by the World Bank [57] have been
criticised, as they were not based on validated health impact
Figure 4. Mean Approved Combined GFATM and Non-GFATM Funding for 87 PfMECs Expressed as US Dollars (USD) Per Capita at Stable P. falciparum
Risk Per Annum
Countries indicated by hatching are those with no areas of stable risk.
doi:10.1371/journal.pmed.0050142.g004
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Financing Global Malaria Controldata [58]. The results published recently by UNICEF and the
RBM partnership [59] suggest that progress is being made in
some countries, and this progress is assumed to be a direct
result of increased availability of funding. There has not been
a detailed comparison of performance targets (judged by
intervention coverage or health impact) against a per capita
ﬁnancial commitment among populations at risk of P.
falciparum malaria. Such an analysis will only be possible when
a temporally congruent series of country-by-country survey
data is assembled. To date only 16 PfMECs have national
survey data on malaria intervention coverage after 2005 [59].
Auditing international health ﬁnancing is difﬁcult [36], and
our analysis and accompanying data (Table S1) come with
additional caveats. The GFATM is transparent in the ﬁnancial
information they provide on funding and is a model for all
donors. The precise contribution of funding for malaria
control to speciﬁc countries by the bilateral donor agencies
between 2002 and 2007 is harder to deﬁne. First, with the
recent exception of USAID and DFID, bilateral agencies make
little attempt to provide disease-speciﬁc, country-speciﬁc
accounts. Second, for all development agencies, malaria
support is hard to separate from general health sector support
or direct-budgetary support that assists human resources,
essential drugs, and infrastructure. These contributions are
substantial in many resource-poor countries, but there is no
obvious method to segregate the malaria-speciﬁc component.
Estimating domestic expenditure on national malaria control
is also difﬁcult to determine. National governments support
their health systems to deliver goods and services, and in many
African countries the single largest disease burden on the
health system is malaria. We have defaulted to using data
provided by the WHO on domestic funding for malaria [32]
and have assumed that these data include a national govern-
ment’s audited budgetary allocation under a speciﬁed line
item labelled ‘‘malaria.’’ Precisely how these ﬁgures were
presented to WHO remain unclear, for example, whether the
reported ﬁgures included funds derived from direct budget-
ary support from bilateral agencies or not. The ﬁdelity of the
information is questionable. Malawi was reported to spend
US$22.2 million p.a., a country ﬁve times smaller than Kenya,
which reported only US$0.082 million government commit-
ment, which in turn was half the value supposedly committed
by its neighbour, Somalia (US$0.16 million), during a period
when the central government in Somalia was not operational.
Deﬁning the ﬁnancial commitments at country levels, from
either provider or recipient sources, limits the overall
capacity of ﬁnancial needs assessments on a country-by-
country basis. Increasing pressure on international donors to
improve the audited country-by-country transparency in
ﬁnancial commitments will make the sorts of equity analysis
presented here possible for all funding partners. National
governments, as partners in the RBM partnership, should be
encouraged to and assisted in developing better metrics to
enumerate annual ﬁnancial ﬂows to malaria control. RBM is
currently undertaking a needs-assessment exercise in 25
African countries, and this should improve the data currently
assembled in Table S1.
The Adequacy of the Global Financial Commitment to
Malaria Control
Most methods of estimating ﬁnancial need assume a similar
costing strategy and package of effective interventions
reaching scales of 80% coverage: insecticide-treated nets;
indoor-residual house spraying; prevention of malaria in
pregnancy; prevention and control of epidemics; effective
case management with artemisinin-based combination ther-
apy combined with improved diagnostics; management of
severe malaria; and supporting structures such as communi-
cation, training, surveillance, and monitoring. The outcomes
of these modelled assumptions of need vary considerably
globally and regionally, largely as a result of variations in
methods used to estimate the denominators of populations at
risk. The earliest attempts by Narasimhan and Attaran [36]
estimated that global needs ranged between US$1.5 billion
and US$2.5 billion p.a. Recent estimates doubled these ﬁgures
to between US$3.8 billion and US$4.5 billion p.a. globally
with per capita needs for Africa of US$2.43, for Asia and
Oceania of US$1.16, and for the Americas of US$0.86 in 2006
[33]. Using a different denominator, Teklehaimanot et al. [60]
estimated that the per capita needs for effective scaling up of
malaria control was US$4.46 in Africa in 2007, or a combined
commitment from all sources of approximately US$3 billion.
Using the range of predicted annual needs we estimate that
there remains a 50%–450% shortfall of funding to achieve
the scaling up of malaria control required worldwide. It
should be noted that these estimates are only for the scaling
up of control and do not even consider the additional
ﬁnancing that might be required for malaria elimination,
where feasible. This shortfall is particularly acute in several
high population density countries with stable P. falciparum
malaria risk. In Africa, where it will be difﬁcult to increase
domestic ﬁnancing appreciably before 2015, there is still a
possible 80%–90% deﬁcit in per capita funding for effective
malaria control.
Analyses, Caveats, and Future Perspectives
There are important epidemiological heterogeneities with-
in our deﬁnition of stable malaria, ranging from less than one
infectious bite from local dominant vectors per person per
year to over ten new infections per person per night. The
prevalence of infection in a community is a useful guide to
the variation in intensity of transmission within areas of
stable endemicity [14,61,62]. In addition, it was recently
demonstrated that the prevalence of infection is lower across
the stable endemic areas of the Americas, much of Asia, and a
larger part of Africa than was previously assumed [13]. The
public health consequences of P. falciparum in areas of low
transmission intensity will be considerably less than those in
areas of more intense transmission [22,63]. However, even in
areas of high transmission the relationship between disease
and its outcome is nonlinear and complex [22,63,64]. We have
not adjusted our analysis of funding allocation according to
the intensity of transmission within and between the stable P.
falciparum–endemic countries for three reasons. First, there is
no adequate description of transmission intensity across the
World that is related to parameters that can be used to deﬁne
the public health burdens at country levels. Second, the
GFATM and RBM do not currently have a working model or
deﬁnition of the projected public health beneﬁts resulting
from ﬁnancing different intervention mixes of known
efﬁcacy under different starting transmission conditions.
Hence, the GFATM uses overall populations at risk rather
than transmission intensity, vector species, or other prox-
imate determinants of infection risk as its guiding mantra for
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standard mix of interventions would be required to meet the
objectives of RBM that were laid out in the late 1990s.
As the malaria control community and many individual
countries reconsider prospects for the elimination of malaria
where feasible, resource needs and matched ﬁnancial expect-
ations may change. It is not clear whether the ﬁnancial needs
of a country predominantly exposed to intense, stable P.
falciparum malaria transmission are greater than those of a
country whose dominant transmission characteristics are of
low intensity. The interventions and their delivery mecha-
nisms may become more expensive as countries prepare to
target focal pockets of infection risk and prevent the re-entry
of transmission into malaria-free areas. The use of stable,
endemic, high disease–burden deﬁnitions of populations at
risk may change, and it may become more ‘‘acceptable’’ to
consider unstable transmission–risk populations as a target
for funding. We believe that the uncertainty around priority
setting based on risk, intervention selection, and the
consequent planning of ﬁnancial needs requires a clear
approach by the GFATM, RBM, and their partners, informed
by the baseline endemicity of malaria within the stable limits
of P. falciparum malaria transmission.
With these caveats our analysis has focussed on appropriate
allocations based on overall PfPAR, but it has not examined the
adequacy of funding. Nor have we considered the political
dimensions of international health ﬁnancing, for example,
whether donor agencies should provide external support to
countries with corrupt administrations or to those whose
national governments spend much less on public health than
onmilitary expansion. These questions are beyond the scope of
the present analysis, but we hope that the biological risk and
country-levelfundingdatainTableS1offeracombinedbasisfor
examining other dimensions and nuances of malaria ﬁnancing.
Conclusion
That more funding is needed to control P. falciparum
malaria is not a new concept, but our analysis highlights the
reality that more is needed in speciﬁc countries and regions
to ensure that the highest concentrations of people at risk
beneﬁt from international support. Without a selective
epidemiological–economic targeting of global malaria con-
trol investment it seems unlikely that international goals to
halve disease burdens by 2015 will be achieved.
Supporting Information
Table S1. PfPAR in 2007 and Malaria Funding Per Annum by Country
Found at doi:10.1371/journal.pmed.0050142.st001 (52 KB XLS).
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Financing Global Malaria ControlEditors’ Summary
Background. Malaria is one of the most common infectious diseases in
the world and one of the greatest global public health problems. The
Plasmodium falciparum parasite causes approximately 500 million cases
each year and over one million deaths. More than 40% of the world’s
population is at risk of malaria.
The Millennium Development Goals (MDGs), established by the United
Nations in 2000, include a target in Goal 6: ‘‘to have halted by 2015 and
begun to reverse the incidence of malaria and other major diseases.’’
Following the launch of the MDG and international initiatives like Roll
Back Malaria, there has been an upsurge in support for malaria control.
This effort has included the formation of the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM) and considerable funding from the US
President’s Malaria Initiative, the World Bank, the UK Department for
International Development, USAID, and nongovernmental agencies and
foundations like the Bill & Melinda Gates Foundation. But it is not yet
clear how equitable or effective the financial commitments to malaria
control have been.
Why Was This Study Done? As part of the activities of the Malaria Atlas
Project, the researchers had previously generated a global map of the
limits of P. falciparum transmission. This map detailed areas where risk is
moderate or high (stable transmission areas where malaria is endemic)
and areas where the risk of transmission is low (unstable transmission
areas where sporadic outbreaks of malaria may occur). Because the level
of funding to control malaria should be proportionate to the size of the
populations at risk, the researchers in this study appraised whether the
areas of greatest need were receiving financial resources in proportion to
this risk. That is, whether there is equity in how malaria funding is
allocated.
What Did the Researchers Do and Find? To assess the international
financing of malaria control, the researchers conducted a audit of
financial commitments to malaria control of the GFATM, national
governments, and other donors for the period 2002 to 2007. To assess
need, they estimated the population at risk of stable P. falciparum
malaria transmission in 2007, building on their previous malaria map.
Financial commitments were identified via online and literature searches,
including the GFATM Web site, the World Malaria Report produced by
WHO and UNICEF, and various other sources of financial information.
Together these data allowed the authors to generate an estimate of the
annual malaria funding allocation per capita population at risk of P.
falciparum.
Of the 87 malaria-endemic countries, 76 received malaria funding
commitments by the end of 2007. Overall, annual funding amounted to
US$1 billion dollars, or less than US$1 per person at risk. Forty percent
came from the GFATM, and the remaining from a mix of national
government and external donors. The authors found great regional
variation in the levels of funding. For example, looking at just the
countries approved for GFATM funding, Myanmar was awarded an
average annual per capita-at-risk amount of US$0.01 while Suriname was
awarded US$147. With all financial commitments combined, ten
countries had per capita annual support of more than US$4 per person,
but 34 countries had less than US$1, including 16 where annual malaria
support was less than US$0.5 per capita. These 16 countries represent
50% of the global population at risk and include seven of the poorest
countries in Africa and two of the most densely populated stable
endemic countries in the world (India and Indonesia).
What Do These Findings Mean? The researchers find that the
distribution of funds across the regions affected by malaria to be
generally appropriate, with the Africa region and low-population-at-risk
areas such as the Americas, the Caribbean, the Middle East, and Eastern
Europe receiving proportionate annual malaria support. But they also
identify large shortfalls, such as in the South East Asia and Western
Pacific regions, which represents 47% of the global population at risk but
received only 17% of GFATM and 24% of non-GFATM support. National
government spending also falls short: for example, in Nigeria, where
more than 100 million people are at risk of stable P. falciparum
transmission, less than US$1 is invested per person per year. These
findings illustrate how important it is to examine financial commitments
against actual needs. Given the gaps between funding support and level
of stable P. falciparum risk, the authors conclude that the goal to reduce
the global burden of malaria by 2015 very likely will not be met with
current commitments. They estimate that there remains a 50%–450%
shortfall in funding needed to scale up malaria control worldwide.
Future research should assess the impact of these funding commitments
and what additional resources will be needed if goals of malaria
elimination are added to malaria control targets.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050142.
  This study is discussed further in a PLoS Medicine Perspective by
Anthony Kiszewski
  The authors of this article have also published a global map of malaria
risk; see Guerra, et al. (2008) PLoS Med 5(2) e38
  Information is available from the Global Fund to Fight AIDS,
Tuberculosis and Malaria
  More information is available on global mapping of malaria risk from
the Malaria Atlas Project
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